Company intelligence / Profile preview

ViroBlock

Jerusalem, Israel

Ownership: Private
Development stage: Other

Overview

ViroBlock completed animal trials on its COVID-19 candidate with promising results. Pre-clinical studies demonstrated that channel blockers identified by the platform could protect cells from viral-induced death while dramatically lowering viral progeny. The technology showed potential to treat current and emerging viral threats.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Evotec (conducted validation study)

Beyond the preview

Go deeper on ViroBlock.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViroBlock.

Explore the full profile